Emeryville, Calif.– Ansa Biotechnologies has announced the launch of an early access program for its groundbreaking 50 kilobase (kb) DNA synthesis service, a major leap forward in the field of synthetic biology. The company’s enzymatic synthesis platform now enables scientists to order long, complex DNA sequences—up to 50 kb in length—in under four weeks, a capability that could significantly accelerate progress in areas such as synthetic genomics, metabolic engineering, agriculture, and advanced therapies.
Ansa’s announcement, made ahead of its participation in the SynBioBeta Conference in San Jose, signals a pivotal moment for researchers long constrained by traditional synthesis limits. Until now, scientists often had to piece together shorter DNA fragments using labor-intensive cloning methods. With Ansa’s new offering, researchers can bypass these limitations and obtain large, ready-to-use DNA constructs with speed and precision.
“For decades, scientists have been handcuffed by short DNA fragments, forced to stitch sequences together in their own labs,” said Ansa CEO Jason T. Gammack. “Ansa is changing the game by delivering longer, more complex DNA with speed, accuracy, and transparency. Our expansion from 600 bases to 7.5 kb and now to 50 kb in just a year demonstrates our commitment to removing barriers for innovators in life science.”
The early access program offers constructs ranging from 7.5 kb to 50 kb, verified using long-read sequencing and proprietary informatics tools to ensure accuracy. Ansa’s technology relies on a proprietary enzymatic process that avoids the harsh chemicals used in traditional methods. This enables the direct synthesis of complex or repetitive sequences that are often challenging for other providers.
Notably, Harvard and MIT professor George Church praised Ansa’s capabilities, citing the company’s successful delivery of difficult 41 kb sequences that other vendors were unable to produce. “The Ansa team is responsive, easy to work with, and consistently follows through,” Church said.
Entirely developed and manufactured in the U.S., Ansa’s DNA products are designed to integrate seamlessly into experimental workflows across a range of disciplines. With its latest advancement, Ansa positions itself as a leader in the next phase of biological engineering, offering researchers the tools to “build without limits and innovate without compromise.”
